ORLANDO, Fla.--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), presented phase I data yesterday from an ongoing phase I/II trial of its novel organic arsenic, ZIO-101 in patients with advanced multiple myeloma. The trial is being conducted by Drs. Berenson (Institute for Myeloma & Bone Cancer Institute), Hussein (Moffitt Cancer Center), Boccia (The Center for Cancer & Blood Disorders), Belch (Cross Cancer Institute) and colleagues and the data was presented at the Annual Meeting of the American Society of Hematology (ASH). Of 14 evaluable patients with progressive myeloma, 6 (43%) responded with disease stabilization after having failed a median of eight prior therapies. Treatment was generally well tolerated, and there was no clinically relevant QT interval prolongation as associated with inorganic arsenic, arsenic trioxide. Enrollment in the phase II portion of the study is ongoing.
